Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions
Authors
Keywords
-
Journal
Journal of Immunology Research
Volume 2020, Issue -, Pages 1-12
Publisher
Hindawi Limited
Online
2020-06-29
DOI
10.1155/2020/9235638
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mechanisms of checkpoint inhibition‐induced adverse events
- (2020) P. Urwyler et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Evolution of molecular targets in melanoma treatment
- (2020) Khanh Bao Tran et al. CURRENT PHARMACEUTICAL DESIGN
- Clinical and molecular insights into BCG immunotherapy for melanoma
- (2020) M. Kremenovic et al. JOURNAL OF INTERNAL MEDICINE
- Prognostic Biomarkers for Melanoma Immunotherapy
- (2020) Christopher G. Twitty et al. Current Oncology Reports
- An alternative pathway for cellular protection in BRAF inhibitor resistance in aggressive melanoma type skin cancer
- (2020) Xiang-Lin Mei et al. CHEMICO-BIOLOGICAL INTERACTIONS
- BRAF V600E mutational load as a prognosis biomarker in malignant melanoma
- (2020) Arrate Sevilla et al. PLoS One
- Contemporary Multidisciplinary Management of Sinonasal Mucosal Melanoma
- (2020) Shorook Na’ara et al. OncoTargets and Therapy
- Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy
- (2020) Nalan Akgul Babacan et al. Current Oncology Reports
- Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls
- (2020) Eli P. Darnell et al. Current Oncology Reports
- Insights into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, ATM, BAP1, and POT1
- (2020) Lorenza Pastorino et al. Cancers
- Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy
- (2020) J. Haanen et al. ANNALS OF ONCOLOGY
- Melanoma and autoimmunity
- (2019) Ion G. Motofei MELANOMA RESEARCH
- Thymine DNA glycosylase as a novel target for melanoma
- (2019) Pietro Mancuso et al. ONCOGENE
- Immune checkpoint inhibitors
- (2019) Enfu Hui JOURNAL OF CELL BIOLOGY
- Unleash the power of the mighty T cells-basis of adoptive cellular therapy
- (2019) Ammar Sukari et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Malignant Melanoma: Autoimmunity and Supracellular Messaging as New Therapeutic Approaches
- (2019) Ion G. Motofei CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Decline of PD ‐1 positive circulating T regulatory cells predicting more favorable clinical outcome of melanoma patients under immune checkpoint blockade
- (2019) T. Gambichler et al. BRITISH JOURNAL OF DERMATOLOGY
- Systemic Therapies for Advanced Melanoma
- (2019) Leonora Bomar et al. DERMATOLOGIC CLINICS
- Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer
- (2019) Yara van Holstein et al. DRUGS & AGING
- Melanoma
- (2019) Conor H. O'Neill et al. JOURNAL OF SURGICAL ONCOLOGY
- Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study
- (2019) Milena Casula et al. BMC CANCER
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
- (2019) Georgina V Long et al. LANCET ONCOLOGY
- Preferences for Immunotherapy in Melanoma: A Systematic Review
- (2019) Ann Livingstone et al. ANNALS OF SURGICAL ONCOLOGY
- Management of V600E and V600K BRAF-Mutant Melanoma
- (2019) Alexandra M. Haugh et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Efficacy and safety of dabrafenib–trametinib in the treatment of unresectable advanced/metastatic melanoma with BRAF‐V600 mutation: A systematic review and network meta‐analysis
- (2019) Nathaly Garzón‐Orjuela et al. Dermatologic Therapy
- Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
- (2019) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Type I interferon (IFN)-inducible Absent in Melanoma 2 proteins in neuroinflammation: implications for Alzheimer’s disease
- (2019) Divaker Choubey Journal of Neuroinflammation
- Intratumoral Immunotherapy—Update 2019
- (2019) Omid Hamid et al. ONCOLOGIST
- Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition
- (2019) Peter Chei-way Pan et al. Current Oncology Reports
- Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
- (2019) Justin C. Moser et al. Cancer Medicine
- Management of pulmonary toxicity associated with immune checkpoint inhibitors
- (2019) Myriam Delaunay et al. European Respiratory Review
- A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma
- (2019) Margreet G. Franken et al. EUROPEAN JOURNAL OF CANCER
- Epidemiology and Risk Factors of Melanoma
- (2019) Stephanie Carr et al. SURGICAL CLINICS OF NORTH AMERICA
- Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy
- (2019) Eva Rajha et al. Gastroenterology Report
- Cardiac Immune Related Adverse Events in Immune Checkpoint Inhibition Therapy
- (2018) Aaron D. Brumbaugh et al. Cardiology in Review
- Vitiligo-like lesions and immune checkpoint inhibition therapy: is it truly an adverse event exclusive to patients with melanoma?
- (2018) E. Rodríguez-Lomba et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management
- (2018) Christophoros Astaras et al. Current Neurology and Neuroscience Reports
- Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan
- (2018) Hisashi Uhara International Journal of Clinical Oncology
- Immunotherapy of melanoma
- (2018) Iwona Lugowska et al. Wspolczesna Onkologia-Contemporary Oncology
- The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma
- (2018) Janine Kimpel et al. Viruses-Basel
- Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
- (2018) Samuel Rosner et al. Cancer Medicine
- Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy
- (2018) Sawsan Rashdan et al. Lancet Respiratory Medicine
- A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma
- (2018) Lukas Krähenbühl et al. NEOPLASIA
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens
- (2018) Romualdo Barroso-Sousa et al. JAMA Oncology
- New insights into the etiopathogenesis of Hashimoto's Thyroiditis: The role of genetics and epigenetics
- (2018) Massimo Ralli et al. AUTOIMMUNITY REVIEWS
- Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy
- (2018) J. Narváez et al. AUTOIMMUNITY REVIEWS
- Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma
- (2018) Francesco S. Mennini et al. CLINICAL DRUG INVESTIGATION
- The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe
- (2018) Florentia Dimitriou et al. Current Oncology Reports
- Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families
- (2018) Thomas P. Potjer et al. INTERNATIONAL JOURNAL OF CANCER
- Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
- (2018) Rodabe N. Amaria et al. NATURE MEDICINE
- Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
- (2018) Yinghong Wang et al. NATURE MEDICINE
- Is earlier better for melanoma checkpoint blockade?
- (2018) Caroline Robert NATURE MEDICINE
- Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time
- (2018) Wouter W. van Willigen et al. Frontiers in Immunology
- Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study
- (2018) Nicolas Delanoy et al. Lancet Haematology
- The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
- (2017) Lieve Brochez et al. EUROPEAN JOURNAL OF CANCER
- Role of interferon in melanoma: old hopes and new perspectives
- (2017) Martina Sanlorenzo et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- Targeted agents and immunotherapies: optimizing outcomes in melanoma
- (2017) Jason J. Luke et al. Nature Reviews Clinical Oncology
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-Related Adverse Effects of Cancer Immunotherapy— Implications for Rheumatology
- (2017) Laura C. Cappelli et al. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
- (2017) Diego Chowell et al. SCIENCE
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Immune system and melanoma biology: a balance between immunosurveillance and immune escape
- (2017) Anna Passarelli et al. Oncotarget
- Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma
- (2017) Hassan Sadozai et al. Frontiers in Immunology
- Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients
- (2017) Arthur E. Frankel et al. NEOPLASIA
- Prediction of the Occurrence of Melanoma and Non-melanoma Skin Cancer in Patients with Vitiligo
- (2016) S Hammoud et al. ACTA DERMATO-VENEREOLOGICA
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Immune-Related Adverse Events From Immune Checkpoint Inhibitors
- (2016) KA Marrone et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma
- (2016) Lavinia Spain et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20/eltrapuldencel-T)
- (2016) Asad Javed et al. Future Oncology
- Safety of administering the canine melanoma DNA vaccine (Oncept) to cats with malignant melanoma – a retrospective study
- (2016) Luminita Sarbu et al. JOURNAL OF FELINE MEDICINE AND SURGERY
- Erratum: The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
- (2016) Danny N. Khalil et al. Nature Reviews Clinical Oncology
- Immune-checkpoint blockade — durable cancer control
- (2016) Elizabeth I. Buchbinder et al. Nature Reviews Clinical Oncology
- Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
- (2016) Krista Dubin et al. Nature Communications
- Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment
- (2016) Andrea Botticelli et al. Oncotarget
- Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
- (2016) Lucie Heinzerling et al. Journal for ImmunoTherapy of Cancer
- Metastatic Melanoma – A Review of Current and Future Treatment Options
- (2015) E Maverakis et al. ACTA DERMATO-VENEREOLOGICA
- Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) R. Dummer et al. ANNALS OF ONCOLOGY
- The Journey from Discoveries in Fundamental Immunology to Cancer Immunotherapy
- (2015) Jacques F.A.P. Miller et al. CANCER CELL
- Immunotherapy Not Working? Check Your Microbiota
- (2015) Nathan R. West et al. CANCER CELL
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Cytotoxic T-Lymphocyte Antigen-4 Blockade in Melanoma
- (2015) Elizabeth I. Buchbinder et al. CLINICAL THERAPEUTICS
- The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
- (2015) Kathleen M. Mahoney et al. CLINICAL THERAPEUTICS
- Therapeutic cancer vaccines
- (2015) Cornelis J.M. Melief et al. JOURNAL OF CLINICAL INVESTIGATION
- From mice to humans: developments in cancer immunoediting
- (2015) Michele W.L. Teng et al. JOURNAL OF CLINICAL INVESTIGATION
- Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
- (2015) Hansje-Eva Teulings et al. JOURNAL OF CLINICAL ONCOLOGY
- Pseudoprogression and Immune-Related Response in Solid Tumors
- (2015) Victoria L. Chiou et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Could microbial therapy boost cancer immunotherapy?
- (2015) A. Snyder et al. SCIENCE
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
- (2015) B. M. Carreno et al. SCIENCE
- Immune Checkpoint Blockade and Interferon-α in Melanoma
- (2015) Imran Rafique et al. SEMINARS IN ONCOLOGY
- Classification of current anticancer immunotherapies
- (2015) Lorenzo Galluzzi et al. Oncotarget
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?
- (2014) I. Chevolet et al. BRITISH JOURNAL OF DERMATOLOGY
- New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape
- (2014) Deepak Mittal et al. CURRENT OPINION IN IMMUNOLOGY
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients
- (2014) E. Cha et al. Science Translational Medicine
- Immunotherapy of melanoma
- (2013) John B.A.G. Haanen EJC SUPPLEMENTS
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Cancer Immunotherapy
- (2013) J. Couzin-Frankel SCIENCE
- Melanoma as a model tumour for immuno-oncology
- (2012) M. Maio ANNALS OF ONCOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Phase 1 Study of Stereotactic Body Radiotherapy and Interleukin-2--Tumor and Immunological Responses
- (2012) S. K. Seung et al. Science Translational Medicine
- Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
- (2011) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Reviews on sun exposure and artificial light and melanoma
- (2011) Sara Gandini et al. PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY
- Advanced Malignant Melanoma: Immunologic and Multimodal Therapeutic Strategies
- (2010) Niels Halama et al. Journal of Oncology
- Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study
- (2009) P. Quaglino et al. ANNALS OF ONCOLOGY
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
- (2008) Naomi N. Hunder et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started